Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Decreases By 35.9%

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) was the target of a significant decline in short interest in January. As of January 15th, there was short interest totalling 5,640,000 shares, a decline of 35.9% from the December 31st total of 8,800,000 shares. Based on an average daily volume of 2,360,000 shares, the short-interest ratio is presently 2.4 days.

Institutional Trading of Reviva Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. EMC Capital Management grew its position in shares of Reviva Pharmaceuticals by 142.0% in the 4th quarter. EMC Capital Management now owns 44,535 shares of the company’s stock valued at $81,000 after purchasing an additional 26,134 shares during the period. Drive Wealth Management LLC acquired a new stake in shares of Reviva Pharmaceuticals in the 4th quarter valued at approximately $36,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Reviva Pharmaceuticals by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock valued at $401,000 after buying an additional 42,376 shares during the last quarter. 63.18% of the stock is owned by institutional investors.

Reviva Pharmaceuticals Stock Performance

Shares of NASDAQ:RVPH opened at $1.77 on Wednesday. Reviva Pharmaceuticals has a 52 week low of $0.60 and a 52 week high of $4.83. The company’s fifty day moving average is $1.73 and its 200-day moving average is $1.34.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on RVPH shares. Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Friday, January 10th. Roth Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. D. Boral Capital reiterated a “buy” rating and set a $15.00 target price on shares of Reviva Pharmaceuticals in a research note on Tuesday, January 21st. HC Wainwright lowered their target price on shares of Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Finally, Roth Mkm started coverage on shares of Reviva Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $7.00 target price for the company. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Reviva Pharmaceuticals currently has an average rating of “Buy” and an average target price of $11.40.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.